Voss MH, Gordon MS, Mita M, Rini B, et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer 2020 Sep 11. pii: 10.1038/s41416-020-01041.
PMID: 32913286